E-ISSN 2149-2530
Review
Anti-IL-5 Biologicals targeting severe late onset eosinophilic asthma
1 Department of Pulmonary Disease, Division of Immunology and Allergy, Koc University, School of Medicine, Istanbul, Turkey  
2 Department of Pulmonary Disease, Division of Immunology and Allergy, School of Medicine, Ankara University, Ankara, Turkey  
Turk Thorac J ; 5: -
DOI: 10.5152/TurkThoracJ.2019.180204
Key Words: Asthma-allergy, eosinophils, interleukin 5, exacerbations, biologicals
Abstract

Improved knowledge about the pathogenesis of asthma has facilitated the development of novel drugs and provided hope for patients with severe asthma. After short and long term success of Omalizumab in severe allergic phenotype, researchers have targeted severe eosinophilic asthma patients who are consisting up to 45% of adult severe asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) play crucial role in the development, maturation, and operation of eosinophils. Nowadays, patients treated with anti-IL-5 biologicals depleting eosinophils experience the positive efficacy of these drugs, especially in regards to the reduction of exacerbation rate. In this review, we aimed shedding light on severe eosinophilic asthma treatment with these new currently available agents selectively targeting IL-5 or its receptor, discussing their usage including pre-treatment concerns such as selecting the target population and choosing the right agent among them, and subsequent assessment of relevant effect and safety issues.

 

Cite this article as: Pür Özyiğit L, Öztürk AB, Bavbek S. Anti-IL-5 Biologicals targeting severe late onset eosinophilic asthma. Turk Thorac J 2019; DOI: 10.5152/TurkThoracJ.2019.180204

Key Words
Authors
All
Author's Corner
Survey
AVES | Copyright © 2019 Turkish Thoracic Society Latest Update: 20.06.2019